-
-
-
-
-
-
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
-
-
-
-
-
-
-
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
-
-
-
-
-
-
-
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
-
-
-
-
-
-
-
Johnson & Johnson (JNJ) Meets EPS Estimate, Beats on Revenue; Offers FY Guidance
-
-
-
-
-
-
-
Goldman Weekly Options Watch
-
-
-
-
-
-
-
Johnson & Johnson (JNJ) PT Raised to $190 at Stifel
-
-
-
-
-
-
-
UBS on why it's still not ready to push the buy button on pharma stocks
-
1,213,757 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

